Cargando…

Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens

ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijazi, Sarah, Visaggio, Daniela, Pirolo, Mattia, Frangipani, Emanuela, Bernstein, Lawrence, Visca, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139391/
https://www.ncbi.nlm.nih.gov/pubmed/30250828
http://dx.doi.org/10.3389/fcimb.2018.00316
_version_ 1783355509337751552
author Hijazi, Sarah
Visaggio, Daniela
Pirolo, Mattia
Frangipani, Emanuela
Bernstein, Lawrence
Visca, Paolo
author_facet Hijazi, Sarah
Visaggio, Daniela
Pirolo, Mattia
Frangipani, Emanuela
Bernstein, Lawrence
Visca, Paolo
author_sort Hijazi, Sarah
collection PubMed
description ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial drugs. In this scenario, the FDA-approved iron mimetic metal Gallium [Ga(III)] has been successfully repurposed as an antimicrobial drug. Ga(III) disrupts ferric iron-dependent metabolic pathways, thereby inhibiting microbial growth. This work provides the first comparative assessment of the antibacterial activity of Ga(NO(3))(3) (GaN), Ga(III)-maltolate (GaM), and Ga(III)-protoporphyrin IX (GaPPIX), belonging to the first-, second- and third-generation of Ga(III) formulations, respectively, on ESKAPE species, including reference strains and multidrug-resistant (MDR) clinical isolates. In addition to the standard culture medium Mueller Hinton broth (MHB), iron-depleted MHB (DMHB) and RPMI-1640 supplemented with 10% human serum (HS) (RPMI-HS) were also included in Ga(III)-susceptibility tests, because of their different nutrient and iron contents. All ESKAPE species were resistant to all Ga(III) compounds in MHB and DMHB (MIC > 32 μM), except Staphylococcus aureus and Acinetobacter baumannii, which were susceptible to GaPPIX. Conversely, the antibacterial activity of GaN and GaM was very evident in RPMI-HS, in which the low iron content and the presence of HS better mimic the in vivo environment. In RPMI-HS about 50% of the strains were sensitive (MIC < 32) to GaN and GaM, both compounds showing a similar spectrum of activity, although GaM was more effective than GaN. In contrast, GaPPIX lost its antibacterial activity in RPMI-HS likely due to the presence of albumin, which binds GaPPIX and counteracts its inhibitory effect. We also demonstrated that the presence of multiple heme-uptake systems strongly influences GaPPIX susceptibility in A. baumannii. Interestingly, GaN and GaM showed only a bacteriostatic effect, whereas GaPPIX exerted a bactericidal activity on susceptible strains. Altogether, our findings raise hope for the future development of Ga(III)-based compounds in the treatment of infections caused by multidrug-resistant ESKAPE pathogens.
format Online
Article
Text
id pubmed-6139391
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61393912018-09-24 Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens Hijazi, Sarah Visaggio, Daniela Pirolo, Mattia Frangipani, Emanuela Bernstein, Lawrence Visca, Paolo Front Cell Infect Microbiol Cellular and Infection Microbiology ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial drugs. In this scenario, the FDA-approved iron mimetic metal Gallium [Ga(III)] has been successfully repurposed as an antimicrobial drug. Ga(III) disrupts ferric iron-dependent metabolic pathways, thereby inhibiting microbial growth. This work provides the first comparative assessment of the antibacterial activity of Ga(NO(3))(3) (GaN), Ga(III)-maltolate (GaM), and Ga(III)-protoporphyrin IX (GaPPIX), belonging to the first-, second- and third-generation of Ga(III) formulations, respectively, on ESKAPE species, including reference strains and multidrug-resistant (MDR) clinical isolates. In addition to the standard culture medium Mueller Hinton broth (MHB), iron-depleted MHB (DMHB) and RPMI-1640 supplemented with 10% human serum (HS) (RPMI-HS) were also included in Ga(III)-susceptibility tests, because of their different nutrient and iron contents. All ESKAPE species were resistant to all Ga(III) compounds in MHB and DMHB (MIC > 32 μM), except Staphylococcus aureus and Acinetobacter baumannii, which were susceptible to GaPPIX. Conversely, the antibacterial activity of GaN and GaM was very evident in RPMI-HS, in which the low iron content and the presence of HS better mimic the in vivo environment. In RPMI-HS about 50% of the strains were sensitive (MIC < 32) to GaN and GaM, both compounds showing a similar spectrum of activity, although GaM was more effective than GaN. In contrast, GaPPIX lost its antibacterial activity in RPMI-HS likely due to the presence of albumin, which binds GaPPIX and counteracts its inhibitory effect. We also demonstrated that the presence of multiple heme-uptake systems strongly influences GaPPIX susceptibility in A. baumannii. Interestingly, GaN and GaM showed only a bacteriostatic effect, whereas GaPPIX exerted a bactericidal activity on susceptible strains. Altogether, our findings raise hope for the future development of Ga(III)-based compounds in the treatment of infections caused by multidrug-resistant ESKAPE pathogens. Frontiers Media S.A. 2018-09-10 /pmc/articles/PMC6139391/ /pubmed/30250828 http://dx.doi.org/10.3389/fcimb.2018.00316 Text en Copyright © 2018 Hijazi, Visaggio, Pirolo, Frangipani, Bernstein and Visca. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Hijazi, Sarah
Visaggio, Daniela
Pirolo, Mattia
Frangipani, Emanuela
Bernstein, Lawrence
Visca, Paolo
Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title_full Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title_fullStr Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title_full_unstemmed Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title_short Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
title_sort antimicrobial activity of gallium compounds on eskape pathogens
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139391/
https://www.ncbi.nlm.nih.gov/pubmed/30250828
http://dx.doi.org/10.3389/fcimb.2018.00316
work_keys_str_mv AT hijazisarah antimicrobialactivityofgalliumcompoundsoneskapepathogens
AT visaggiodaniela antimicrobialactivityofgalliumcompoundsoneskapepathogens
AT pirolomattia antimicrobialactivityofgalliumcompoundsoneskapepathogens
AT frangipaniemanuela antimicrobialactivityofgalliumcompoundsoneskapepathogens
AT bernsteinlawrence antimicrobialactivityofgalliumcompoundsoneskapepathogens
AT viscapaolo antimicrobialactivityofgalliumcompoundsoneskapepathogens